Scopolamine

Introduction Overview

Generic Name

Scopolamine

Brand Name

Transderm Scop

Dosage Form

Transdermal patch (extended release)

Drug Class

Anticholinergic antiemetics, Anticholinergics / antispasmodics

Pharmacokinetics

Absorption:
Scopolamine delivered via a transdermal patch offers sustained and controlled absorption through the skin. The drug is absorbed through the dermis at a slow and continuous rate, maintaining therapeutic plasma concentrations for up to 72 hours. On application behind the ear, absorption begins within a few hours, typically reaching effective plasma levels within 4 hours, which coincides with its onset of clinical efficacy in preventing nausea and vomiting. The transdermal route avoids first-pass hepatic metabolism, enhancing bioavailability compared to oral administration, reducing systemic gastrointestinal side effects. Factors influencing absorption include skin integrity, site of application, skin temperature, and hydration status.

Distribution:
Once absorbed, scopolamine is widely distributed throughout the body, crossing the blood-brain barrier effectively due to its lipophilic nature. This central nervous system penetration is critical for its antiemetic and anticholinergic actions within the brain, notably in the vestibular system and area postrema (chemoreceptor trigger zone). The volume of distribution is relatively large, reflecting extensive tissue uptake including peripheral tissues and the CNS. Scopolamine also crosses the placenta and appears in small amounts in breast milk.

Metabolism:
Scopolamine undergoes hepatic metabolism primarily through enzymatic pathways involving hydrolysis and conjugation. The drug is metabolized to inactive metabolites, with minimal involvement of cytochrome P450 enzymes, thereby reducing the likelihood of significant hepatic drug-drug interactions. The metabolic rate can be influenced by hepatic function, age, and other comorbidities.

Elimination:
The elimination of scopolamine and its metabolites occurs predominantly via renal excretion. The elimination half-life after transdermal administration is approximately 9.5 hours in plasma, but due to sustained release, plasma levels are maintained throughout the 72-hour patch application. Renal clearance may be reduced in patients with kidney impairment, potentially necessitating careful monitoring. Complete elimination occurs over several days post patch removal. Minimal excretion occurs in feces.

Dosage Forms

Available Dosage Forms:
Scopolamine is commercially available primarily as a transdermal patch designed for extended release. The patch is thin, adhesive, designed for application on the skin behind the ear. This formulation allows prolonged systemic delivery over approximately 72 hours.

Dosages for Adults and Adolescents:
- Prevention of postoperative nausea and vomiting: Apply one patch behind the ear the evening before surgery, maintaining it for 24 hours. This provides continuous therapeutic levels during the critical postoperative period.
- Prevention of motion sickness: One patch is applied at least 4 hours before exposure to motion sickness-inducing stimuli and may be worn up to 3 days. The patch should be replaced every 3 days if continued prophylaxis is necessary.
- Use in children is not recommended due to lack of established safety and efficacy.

Specific Patient Populations:
- Pediatric use has not been established; hence, administration in children is not recommended.
- Geriatric patients may use the patch with caution because of possible age-related hepatic and renal impairment affecting drug metabolism and clearance.
- Patients with liver or kidney disease require careful monitoring, though specific dosing adjustments are not well defined.
- Patients with narrow-angle glaucoma or urinary retention should avoid use due to exacerbation risk.
- The patch should not be cut or altered, and only one patch should be used at a time to prevent toxicity.

Mechanism Of Action

Scopolamine is a potent anticholinergic agent; it exerts its pharmacological effects primarily by blocking muscarinic acetylcholine receptors (mAChRs), particularly the M1 and M2 subtypes, which are widely distributed in the central nervous system and peripheral autonomic sites. The blockade of these receptors reduces the excitatory cholinergic transmission.

In the central nervous system, scopolamine acts mainly on the vestibular nuclei and the vomiting center in the medulla oblongata, particularly targeting the area postrema, which is rich in muscarinic receptors. By inhibiting the cholinergic input into these centers, scopolamine suppresses the neural pathways responsible for nausea and vomiting induced by vestibular stimuli, anesthesia, narcotics, and surgery.

At a cellular level, scopolamine prevents acetylcholine from binding to muscarinic receptors, inhibiting activating second messenger systems such as phosphoinositide turnover and cAMP-related pathways. This leads to decreased parasympathetic nervous system outflow, producing a calming effect on gastrointestinal smooth muscle and reducing gastrointestinal motility. This action complements its antiemetic effects by stabilizing gut activity and decreasing stimuli that could provoke nausea.

Compared to other anticholinergic agents like atropine, scopolamine has greater CNS penetration and longer duration of action when delivered via transdermal patch. Its lipophilicity facilitates this CNS penetration. Clinical studies have shown that transdermal scopolamine effectively prevents motion sickness and postoperative nausea, often with fewer systemic atropine-like side effects. Additionally, unlike antihistamine-based antiemetics, scopolamine specifically targets cholinergic mechanisms of vomiting, providing alternative or adjunctive therapeutic options. Ongoing research explores scopolamine’s utility in neuropsychiatric disorders due to its muscarinic antagonism effects on cognition and mood.

Pharmacological Actions

Anticholinergic activity via competitive antagonism of muscarinic receptors.
Central nervous system depressant effects contributing to antiemetic action.
Reduction of gastrointestinal motility and secretion by parasympathetic inhibition.
Antispasmodic effects on smooth muscles in the gastrointestinal and genitourinary tracts.
Peripheral parasympatholytic effects leading to decreased salivary and respiratory secretions.
Inhibition of vestibular stimulation transmission to the vomiting center.
Calming effect on the central autonomic nervous system, reducing nausea and vomiting.
Transient pupil dilation (mydriasis) by blocking muscarinic receptors in the eye.
Sedative properties contributing to relief from motion sickness discomfort.
Minimal effect on nicotinic receptors, differentiating from ganglionic blockers.
Long-acting systemic effect when administered transdermally with steady plasma levels.
Decreased gastrointestinal secretions and motility contributing to antiemetic activity.
Potential to cause CNS side effects including dizziness, confusion, and hallucinations at high doses.
Blocks acetylcholine-mediated parasympathetic responses thus reducing muscle spasms.

Therapeutic Or Clinical Uses

Prevention of nausea and vomiting associated with motion sickness.
Prophylaxis of postoperative nausea and vomiting following anesthesia and surgery.
Management of vestibular disturbances including vertigo related to inner ear disorders.
Adjunctive treatment of gastrointestinal spasms and irritable bowel syndrome (off-label).
Prevention of nausea induced by narcotic analgesics.
Used in palliative care to alleviate nausea in patients with advanced illnesses.
Relief of excessive salivation and respiratory secretions in preoperative settings.
Treatment option for certain types of neurogenic bladder dysfunction (off-label).
Research clearance for potential use in psychiatric disorders related to cholinergic dysfunction.
Adjunctive therapy for motion sickness during long sea voyages or air travel.
Used in diagnostic procedures to reduce gastrointestinal motility.
Application in preventing post-anesthetic vomiting in high-risk surgical patients.
Treatment of acute episodes of vertigo when other therapies are contraindicated or ineffective.
Potential use in relief of muscarinic side effects in certain medication overdoses.
Occasional off-label use to reduce extrapyramidal symptoms caused by antipsychotic drugs.

Side Or Adverse Effects

Dry mouth (xerostomia), the most common systemic anticholinergic side effect.
Dizziness and lightheadedness especially upon standing or during activities requiring alertness.
Blurred vision due to transient mydriasis and cycloplegia affecting accommodation.
Drowsiness or unusual sedation which may impair the ability to perform hazardous tasks.
Confusion, memory impairment, and cognitive dysfunction particularly in elderly patients.
Headache and sensations of headache or head pressure.
Skin reactions at the site of patch application such as burning, itching, redness, or rash.
Increased intraocular pressure potentially precipitating acute angle-closure glaucoma.
Urinary retention or difficulty in urinating due to effects on bladder detrusor muscle.
Restlessness, agitation, and nervousness in sensitive individuals.
Visual disturbances including seeing halos around lights or altered color perception.
In rare instances, hallucinations or delusions particularly with overdose or in sensitive populations.
Increased heart rate (tachycardia) and palpitations secondary to vagal blockade.
Nausea or gastrointestinal discomfort paradoxically despite its antiemetic use.
Overdose symptoms including dryness of skin, decreased sweating, flushing, seizure, and severe drowsiness.

Precautions

Avoid use in patients with narrow-angle glaucoma due to risk of precipitating acute angle closure.
Cautious use in patients with urinary retention, prostatic hypertrophy, or bladder neck obstruction.
Monitor elderly patients closely for CNS effects such as confusion, dizziness, or hallucinations.
Avoid exposure of patch to eyes to prevent blurred vision and mydriasis.
Do not use multiple patches simultaneously to prevent toxicity.
Use with caution in patients with liver or kidney impairment due to altered metabolism and excretion.
Patients should avoid driving or operating heavy machinery until they know how the drug affects them.
Consider potential additive CNS depressant effects when used with alcohol or other CNS depressants.
Inform healthcare providers before MRI scans as the aluminum in the patch may cause burns requiring patch removal prior to the procedure.
Use with caution in patients with history of seizures or psychosis; monitor for worsening symptoms.
Not recommended for use in pediatric populations due to lack of established safety and efficacy data.
Use cautiously in patients with gastrointestinal obstruction or ileus as scopolamine may worsen symptoms.
Avoid concurrent use with other anticholinergic medications to reduce risk of cumulative adverse effects.
Patients with a history of hypersensitivity to scopolamine or similar compounds should avoid the drug.
Monitor for signs of anticholinergic toxicity particularly in long-term or high-dose use.

Warnings

Risk of acute angle-closure glaucoma; patients should be educated to report eye pain, vision changes, or halos immediately.
Potential for CNS toxicity including confusion, delirium, hallucinations, especially in elderly or debilitated patients.
The transdermal patch contains aluminum which increases risk of skin burns during MRI; patch must be removed before MRI scanning.
May cause significant drowsiness and impaired coordination, increasing risk of falls or accidents.
May exacerbate symptoms of urinary retention or cause difficulty in urination.
Patients with a history of seizure disorders may experience increased seizure frequency.
Do not apply patch to broken, irritated, or damaged skin to avoid unpredictable absorption and local irritation.
Overdose can cause severe anticholinergic syndrome requiring immediate medical attention.
Concomitant use with other CNS depressants can cause additive sedation and respiratory depression.
Do not use during pregnancy unless clearly needed due to unknown risk of seizures in women with preeclampsia.
Risk of severe dry mouth leading to increased dental caries and oral infections with prolonged use.
Patch should not be cut or altered as it disrupts the controlled release mechanism and dosing accuracy.
Avoid sudden discontinuation in chronic users to prevent rebound effects or worsening of symptoms.
Use in patients with psychosis or severe psychiatric conditions requires close monitoring due to risk of exacerbation.
Not recommended for pediatric use due to insufficient safety data and potential for toxicity.

Contraindication

Known hypersensitivity or allergy to scopolamine or any component of the patch.
Patients with narrow-angle glaucoma due to risk of precipitating acute angle closure.
History of urinary tract obstruction or severe bladder neck obstruction.
Patients with myasthenia gravis, as anticholinergics may exacerbate muscle weakness.
Severe hepatic or renal impairment lacking safety data contraindicates use until evaluated by physician.
Patients with obstructive gastrointestinal diseases such as pyloric stenosis or intestinal atony.
Severe ulcerative conditions of the gastrointestinal tract that may worsen with decreased motility.
Those with known or suspected hypersensitivity to belladonna alkaloids or other anticholinergics.
Individuals with untreated or unstable psychiatric disorders where anticholinergic effects may worsen symptoms.
Contraindicated in patients with delayed gastric emptying or toxic megacolon.
Not recommended for use in children due to risk of severe side effects and lack of efficacy data.
Patients with narrow-angle glaucoma or conditions predisposing to intraocular pressure elevation.
Use during pregnancy or lactation only if clearly needed and benefits outweigh risks.
Concomitant use with potassium citrate is not recommended due to potential interactions.
Contraindicated in patients undergoing MRI if patch removal is not performed to avoid skin burns.

Drug Interactions

Potassium citrate is contraindicated with scopolamine due to potential interaction.
Concomitant use with anticholinergic agents such as atropine, biperiden, benztropine increases risk of additive anticholinergic effects.
Interaction with central nervous system depressants including benzodiazepines, barbiturates, opioids, and sedative antihistamines may enhance sedation and respiratory depression.
Use with tricyclic antidepressants (amitriptyline, clomipramine, desipramine) may increase anticholinergic side effects and toxicity.
Concurrent use with antipsychotics (clozapine, fluphenazine, pimozide) may enhance CNS side effects such as confusion and delirium.
Potential interaction with muscle relaxants such as cyclobenzaprine and carisoprodol potentiating CNS depression.
Co-administration with antihistamines (diphenhydramine, chlorpheniramine) escalates anticholinergic burden and sedation.
Opioid analgesics (hydrocodone, morphine, tramadol) may have augmented CNS depressant and anticholinergic effects when used with scopolamine.
Interaction with drugs causing urinary retention (oxybutynin, tolterodine) exacerbates urinary side effects.
Concomitant use with monoamine oxidase inhibitors (MAOIs) may potentiate anticholinergic adverse reactions.
Use with sedatives or sleeping agents (eszopiclone, zolpidem) may increase sedation and cognitive impairment.
Potentiation of scopolamine’s effects may occur with other antimuscarinic agents (glycopyrrolate, darifenacin).
Concurrent use with alcohol intensifies drowsiness, dizziness, and CNS depressive effects.
Drugs with anticholinergic properties including some anti-Parkinson agents (amantadine, benztropine) increase side effect incidence.
Use with magnesium oxybate and calcium oxybate may enhance CNS depressant effects.

Preparations Of The Drug

Transderm Scop: Transdermal patch delivering extended-release scopolamine over 72 hours.
Transderm-V: Alternative brand available in Canada with similar transdermal formulation.
Injectable scopolamine formulations (hyoscine injection) used for different clinical indications and settings.
Oral and ophthalmic formulations are available but not indicated for motion sickness or postoperative nausea prevention typically.
The transdermal patch is packaged with protective pouches to maintain sterility and stability prior to application.
Patches are designed for single use and disposable by folding with adhesive sides together.
Patches contain a dose typically delivering approximately 1.5 mg scopolamine over 72 hours.
Skin adhesives used in the transdermal system ensure secure attachment during bathing or swimming.
Patch includes aluminum backing which requires removal before MRI procedures to prevent burns.
Patient medication guides and detailed application instructions accompany the transdermal patches.
Available commercially as prescription-only products requiring healthcare provider supervision.
Packaging includes warnings about potential drug interactions, side effects, and proper disposal methods.
Some preparations include alternate sizes or dosing strengths for clinical adjustments (less common).
Specialized preparation forms such as compound topical creams or sprays exist but are not widely used clinically.
Manufacturers provide specific storage recommendations including room temperature maintenance and avoidance of moisture.